OGAP® Discovery Platform
OBT’s proprietary platform, OGAP®, is the world’s largest cancer specific membrane protein library, directly measuring plasma membrane protein expression in patient tumors. OGAP® characterises cell surface protein expression of tumours and healthy tissue to identify novel cell-surface cancer targets to develop first-in-class antibody drug conjugate (ADC), Bispecific T-cell Engager (BiTE®) and Chimeric Antigen Receptor (CAR) therapeutics.
OBT identified CD205 using OGAP®, a receptor overexpressed on tumor cells (gastric, lung & ovarian cancer) and some immune suppressive cells, leading to the development of OBT076, an ADC targeting CD205.
The platform enables access to a wide range of targets which can be leveraged in external partnerships with leaders in the oncology space. Existing partnerships include Boehringer Ingelheim and Kite.
OBT identified CD205 using OGAP®, a receptor overexpressed on tumor cells (gastric, lung & ovarian cancer) and some immune suppressive cells, leading to the development of OBT076, an ADC targeting CD205.
The platform enables access to a wide range of targets which can be leveraged in external partnerships with leaders in the oncology space. Existing partnerships include Boehringer Ingelheim and Kite.
